Janjigian, Y. Y. Et Al. 2024. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL , 245-246.

Janjigian, Y. Y., Al-Batran, S., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., ... Hyung, W. J.(2024). Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, 245-246.

Janjigian, Yelena Et Al. "Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study," JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, 245-246, 2024

Janjigian, Yelena Y. Et Al. "Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study." JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, pp.245-246, 2024

Janjigian, Y. Y. Et Al. (2024) . "Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study." JOURNAL OF CLINICAL ONCOLOGY , no.3_SUPPL, pp.245-246.

@article{article, author={Yelena Y. Janjigian Et Al. }, title={Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2024, pages={245-246} }